Laminar Pharma Scientific Advisory Board (SAB) has held a meeting today in Madrid were a group of leading scientist had discussed the molecular basis and mechanism of action of the novel MLT-based LP226A1, a compound in Laminar Pharma’s pipeline currently in preclinical development as a potential treatment against Alzheimer’s Disease (AD). In this meeting, two world renowned scientific experts in lipid science and cell membranes have joined as new members of Laminar Pharma’s SAB: Dr. Nicolson and Dr. Epand.

Prof. G.L. Nicolson is currently President, Chief Scientific Officer and Research Professor at the Institute for Molecular Medicine in Huntington Beach (California). In 1972, Dr. Nicolson together with Dr. S.J. Singer described the theory called the fluid mosaic model about the structure of cell membranes. Dr. Richard M. Epand is Professor Emeritus of Biochemistry and Biomedical Sciences at the University of Mc Master in Hamilton (Canada). “We are very proud of the incorporation of these two reputed scientist to Laminar Pharma’s SAB, which will significantly contribute to boost the scientific potential and scope of our innovative R&D programs” said Vicenç Tur, Laminar Pharma’s CEO.

The SAB meeting held today was lead by SAB’s president, Prof. Xavier Busquets, and counted also with a significant contribution from Prof. Pablo Escriba, CSO and main co-founder of Laminar Pharma.